Association of biomarkers (BMs) with efficacy of adjuvant nivolumab (NIVO) vs placebo (PBO) in patients with resected stage IIB/C melanoma (CA209-76K).
Georgina V. Long(Westmead Hospital), Michele Del Vecchio(Fondazione IRCCS Istituto Nazionale dei Tumori), John M. Kirkwood(UPMC Hillman Cancer Center), Daniel J. Tenney(Bristol-Myers Squibb (Germany)), Vanna Chiarion‐Sileni(Centre Hospitalier Universitaire Brugmann), Janis M. Taube(Johns Hopkins Hospital), Peter Mohr(Elbe Kliniken Stade-Buxtehude), Jeffrey S. Weber(NYU Langone Health), Christoph Höeller(Medical University of Vienna), Caroline Dutriaux(Centre Hospitalier Universitaire de Bordeaux), Maurice Lobo(Bristol-Myers Squibb (United States)), Jean‐Jacques Grob, Carmen Loquai(Johannes Gutenberg University Mainz), Corey Ritchings(Bristol-Myers Squibb (United States)), Brian Gastman(Cleveland Clinic Lerner College of Medicine), Wenjia Wang(Bristol-Myers Squibb (United States)), Hao Tang(Central South University), Alexander Christopher Jonathan Van Akkooi(Melanoma Institute Australia), Federico Campigotto(Bristol-Myers Squibb (United States)), Sonia Dolfi(Bristol-Myers Squibb (United States))
Cited by 13
Related Papers
Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer
|New England Journal of Medicine|2012|12.6k
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
|New England Journal of Medicine|2015|9.4k
Improved Survival with Vemurafenib in Melanoma with BRAF V600E Mutation
|New England Journal of Medicine|2011|7.7k
Nivolumab in Previously Untreated Melanoma without <i>BRAF</i> Mutation
|New England Journal of Medicine|2014|5.3k